T. Shimomura

发表

Biological characterization of 2-aminothiazole-derived Cdk4/6 selective inhibitor in vitro and in vivo

H. Hirai, T. Shimomura, Makiko Kobayashi, 2010, Cell cycle.

Cell death induction in resting lymphocytes by pan-Cdk inhibitor, but not by Cdk4/6 selective inhibitor

H. Hirai, T. Shimomura, Makiko Kobayashi, 2011, Investigational New Drugs.

Potent anti-tumor activity of a macrocycle-quinoxalinone class pan-Cdk inhibitor in vitro and in vivo

H. Hirai, T. Shimomura, Makiko Kobayashi, 2011, Investigational New Drugs.

Expression levels of p 18 INK 4 C modify the cellular efficacy of cyclin-dependent kinase inhibitors via regulation of Mcl-1 expression in tumor cell lines

H. Hirai, T. Shimomura, T. Eguchi, 2009 .

The ATM-related Tel1 protein of Saccharomyces cerevisiae controls a checkpoint response following phleomycin treatment.

Kunihiro Matsumoto, K. Sugimoto, T. Shimomura, 2003, Nucleic acids research.

The Plasticity of Dendritic Cell Responses to Pathogens and Their Components

Giovanna Lucchini, Paolo Plevani, G. Lucchini, 2001 .

The RAIG family member, GPRC5D, is associated with hard-keratinized structures.

T. Shimomura, Tadahiro Nambu, S. Inoue, 2004, The Journal of investigative dermatology.

Rfc5, a small subunit of replication factor C complex, couples DNA replication and mitosis in budding yeast.

K. Matsumoto, Kunihiro Matsumoto, K. Sugimoto, 1996, Proceedings of the National Academy of Sciences of the United States of America.

Expression levels of p18 INK4C modify the cellular efficacy of cyclin-dependent kinase inhibitors via regulation of Mcl-1 expression in tumor cell lines

H. Hirai, T. Shimomura, T. Eguchi, 2009 .

MK-5108, a Highly Selective Aurora-A Kinase Inhibitor, Shows Antitumor Activity Alone and in Combination with Docetaxel

T. Shimomura, Koji Ichikawa, Shinichi Hasako, 2010, Molecular Cancer Therapeutics.

Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibition.

A. Iwama, P. Richardson, T. Hideshima, 2014, Cancer research.

Rfc5, a replication factor C component, is required for regulation of Rad53 protein kinase in the yeast checkpoint pathway

K. Matsumoto, S. Ando, K. Sugimoto, 1997, Molecular and cellular biology.

[Novel anti-cancer compounds targeting the cell cycle].

H. Hirai, T. Shimomura, H. Kotani, 2009, Nihon yakurigaku zasshi. Folia pharmacologica Japonica.

Rfc5, in Cooperation with Rad24, Controls DNA Damage Checkpoints throughout the Cell Cycle inSaccharomyces cerevisiae

Kunihiro Matsumoto, K. Sugimoto, T. Shimomura, 2000, Molecular and Cellular Biology.

Functional and Physical Interaction between Rad24 and Rfc5 in the Yeast Checkpoint Pathways

S. Ando, Kunihiro Matsumoto, K. Sugimoto, 1998, Molecular and Cellular Biology.

Expression levels of p18INK4C modify the cellular efficacy of cyclin-dependent kinase inhibitors via regulation of Mcl-1 expression in tumor cell lines

H. Hirai, T. Shimomura, T. Eguchi, 2009, Molecular Cancer Therapeutics.

Abstract C177: TAS-117, a highly selective non-ATP competitive inhibitor of AKT demonstrated antitumor activity in combination with chemotherapeutic agents and molecular targeted drugs.

T. Abe, T. Shimomura, Koji Ichikawa, 2013 .

Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibition.

A. Iwama, P. Richardson, T. Hideshima, 2014, Cancer research.